Grant application undergo a rigorous review process and are awarded on the basis of scientific merit in relation to Alzheimer’s Research UK’s remit, suitability for the scheme applied for, and open competition.
Alzheimer’s Research UK is a member of the Association of Medical Research Charities (AMRC) and follows their guidelines for best practice in peer review. We also abide by conflict of interest policy throughout the review process.
The scientific merit of an application and the track record of the applicants are the key determinants of outcome, although the strength of the dementia research environment within the Host institution is also considered.
Grants are reviewed by distinct review panels, depending on the grant scheme applied to and the expertise required to review them. It is therefore important that applications are submitted to the most appropriate grant scheme.
A typical review process for applications submitted through our response mode funding schemes is demonstrated below. However, please refer to our grant schemes page for more information on the review processes for individual schemes.
Research guidelines and policies
Useful policies and guidelines relevant to all of our grant schemes.
This distinguished group of some of the world’s leading dementia research experts reviews the applications we receive to most of our grant schemes before making recommendations to our Trustees.
The Clinical Trials Advisory Panel (CTAP) is composed of UK and international experts on dementia, statistics, clinical pharmacology and research governance.
The Dementia Consortium aims to expedite the development of new drugs for dementia by supporting research into novel targets for neurodegeneration.
The ADAG is composed of drug discovery experts from both industry and academia, based in the UK and beyond, and participates in the annual reviews of ARUK’s Drug Discovery institutes, who together form the ARUK Drug Discovery Alliance.